Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Wheeler

Showing results (201-210 of 454) with videos related to

Pageof 46
Sort By:
Kidney International|November 18, 2017
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammationBenjamin C Storey, Natalie Staplin, Richard Haynes, et al.
Clinical Kidney Journal|November 3, 2022
Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohortCarol Pollock, Glen James, Juan Jose Garcia Sanchez, et al.
Prevention Science : the Official Journal of the Society for Prevention Research|February 18, 2022
Neighborhood Deprivation is Associated with Increased Risk of Prenatal Smoke ExposureDavid C Wheeler, Joseph Boyle, D Jeremy Barsell, et al.
Clinical Transplantation|October 15, 2013
Early changes in scores of chronic damage on transplant kidney protocol biopsies reflect donor characteristics, but not future graft functionBen Caplin, Kristin Veighey, Arundathi Mahenderan, et al.
Kidney International|March 22, 2026
A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney diseaseDavid Z I Cherney, Karen Bonefeld, Glenn Crater, et al.
Kidney International|April 30, 2015
High cardiovascular event rates occur within the first weeks of starting hemodialysisKai-Uwe Eckardt, Iain A Gillespie, Florian Kronenberg, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 5, 2026
Sex Associated Biomarker Differences in Chronic Kidney Disease Progression and MortalityThomas McDonnell, Anthony Onoja, Nicolas Vuilleumier, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 4, 2022
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosisVandana S Mathur, David A Bushinsky, Lesley Inker, et al.
Kidney International Reports|April 18, 2023
Health Care Resource Utilization and Related Costs of Patients With CKD From the United States: A Report From the DISCOVER CKD Retrospective CohortJuan Jose Garcia Sanchez, Glen James, Juan Jesus Carrero, et al.
Diabetes, Obesity & Metabolism|March 21, 2023
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCEMichael A Tsoukas, Vincent Woo, Sheldon W Tobe, et al.
Pageof 46

Showing results (201-210 of 454) with videos related to

Sort By:
Pageof 46
Kidney International|November 18, 2017
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammationBenjamin C Storey, Natalie Staplin, Richard Haynes, et al.
Clinical Kidney Journal|November 3, 2022
Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohortCarol Pollock, Glen James, Juan Jose Garcia Sanchez, et al.
Prevention Science : the Official Journal of the Society for Prevention Research|February 18, 2022
Neighborhood Deprivation is Associated with Increased Risk of Prenatal Smoke ExposureDavid C Wheeler, Joseph Boyle, D Jeremy Barsell, et al.
Clinical Transplantation|October 15, 2013
Early changes in scores of chronic damage on transplant kidney protocol biopsies reflect donor characteristics, but not future graft functionBen Caplin, Kristin Veighey, Arundathi Mahenderan, et al.
Kidney International|March 22, 2026
A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney diseaseDavid Z I Cherney, Karen Bonefeld, Glenn Crater, et al.
Kidney International|April 30, 2015
High cardiovascular event rates occur within the first weeks of starting hemodialysisKai-Uwe Eckardt, Iain A Gillespie, Florian Kronenberg, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 5, 2026
Sex Associated Biomarker Differences in Chronic Kidney Disease Progression and MortalityThomas McDonnell, Anthony Onoja, Nicolas Vuilleumier, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 4, 2022
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosisVandana S Mathur, David A Bushinsky, Lesley Inker, et al.
Kidney International Reports|April 18, 2023
Health Care Resource Utilization and Related Costs of Patients With CKD From the United States: A Report From the DISCOVER CKD Retrospective CohortJuan Jose Garcia Sanchez, Glen James, Juan Jesus Carrero, et al.
Diabetes, Obesity & Metabolism|March 21, 2023
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCEMichael A Tsoukas, Vincent Woo, Sheldon W Tobe, et al.
Pageof 46